Collaboration with Spiber Featured in Nikkei Sangyo Shimbun
Our collaboration with Spiber Inc. was featured in the digital edition of Nikkei Sangyo Shimbun on May 20, 2022.
The article introduces the results of the joint research that began in 2020, along with comments from Epistra’s researchers. The article highlights how Spiber is leveraging AI technology in its research, and a researcher from Spiber commented that by using Epistra’s experiment optimization system, “results that used to take two years can now be obtained in just a few weeks.”
In this joint research, Epistra’s proprietary solution “Epistra Accelerate” is being used to drive the automation and optimization of experiments.
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.